ANI Pharmaceuticals
ANIP
157 hedge funds and large institutions have $379M invested in ANI Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 58 increasing their positions, 47 reducing their positions, and 25 closing their positions.
54% more ownership
Funds ownership: 0% → 54% (+54%)
23% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $399M → $379M (-$19.5M)
8% less funds holding
Funds holding: 170 → 157 (-13)
33% less call options, than puts
Call options by funds: $6.65M | Put options by funds: $9.9M
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$15.6M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$15.1M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.65M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$4.12M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.66M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NIT
176
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$86K | -1,300 | Closed |
|
177
Walleye Trading
New York
| – | -$60K | -900 | Closed |
|
|
NC
178
NewSquare Capital
Newtown Square,
Pennsylvania
| – | -$3K | -38 | Closed |
|
|
PFBT
179
Parkside Financial Bank & Trust
Saint Louis,
Missouri
| – | +$245 | +4 | New |
|
|
AA
180
Ancora Advisors
Cleveland,
Ohio
| – | +$367 | +6 | New |
|
ANIP Hedge Fund Activity: Q4 2016 in Review
157 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2016, worth a combined $379M — down 4.9% from $399M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ANIP and 15 opened new positions — a net loss of 10 holders — while 47 trimmed existing stakes and 58 added.
The largest buyer was Perceptive Advisors, adding an estimated $15.6M. The largest seller was Consonance Capital Management, cutting an estimated $9.88M.
- 157 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2016, down from 170 in Q3 2016.
- Funds reported $379M of ANI Pharmaceuticals stock for Q4 2016, down 4.9% quarter-over-quarter.
- 15 funds opened new ANI Pharmaceuticals positions in Q4 2016 and 25 closed out, a net change of -10 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2016 was Perceptive Advisors, an estimated $15.6M added.
- The largest ANI Pharmaceuticals seller in Q4 2016 was Consonance Capital Management, an estimated $9.88M sold.
Based on aggregated 13F filings for Q4 2016.